Senseonics shares climbed 14% on January 8, 2026, following the announcement that Eversense 365 became the first one-year implantable continuous glucose monitor (CGM) integrated with an automated insulin delivery (AID) system. Trading volume surged to more than 9 million shares, nearly triple its three-month daily average. Institutional investors increased their positions by 8% over the past week, according to regulatory filings, reflecting heightened confidence in Senseonics’ growth trajectory as the company moves into the AID market.

The integration pairs Senseonics’ Eversense 365—capable of delivering glucose readings every five minutes for up to 365 days—with Sequel MedTech’s twiist™ AID system, which uses proprietary iiSure™ technology for direct insulin volume measurement and occlusion detection up to nine times faster than competing pumps. The first commercial patients received the combined system at leading diabetes centers in California and Massachusetts. Clinical data presented at the Endocrine Society meeting in December showed a 30% reduction in glycemic variability and a 25% increase in time-in-range compared with traditional CGM-pump setups.

Senseonics and Sequel have targeted broad availability of the twiist–Eversense 365 integration by March 2026, with pricing set at $7,200 per year for the implantable sensor and $4,500 for the pump system. Analysts estimate this could add $85 million in incremental revenue for Senseonics in fiscal 2026, representing a 40% uplift over last year’s CGM sales. Reimbursement negotiations are underway with key payers, and management expects to finalize coverage agreements covering 80% of the U.S. type 1 diabetes population by mid-year.